Core Insights - Immix Biopharma, Inc. has appointed Nancy T. Chang to its Board of Directors, who is a notable biotechnology leader and former CEO of Tanox, Inc. [1][2] - Dr. Chang's leadership at Tanox led to the development of several FDA-approved drugs, generating over $5 billion in sales [2] - Immix Biopharma is focused on developing cell therapies for AL Amyloidosis and other serious diseases, with its lead candidate being NXC-201, a CAR-T cell therapy [3] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMMX [3] - The company is developing NXC-201, which is currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] Product Development - The NEXICART-2 study for NXC-201 has met its primary endpoint at interim results presented at ASCO 2025 [3] - The therapy features a "digital filter" designed to eliminate non-specific activation [3]